HRTX vs. XBI
Compare and contrast key facts about Heron Therapeutics, Inc. (HRTX) and SPDR S&P Biotech ETF (XBI).
XBI is a passively managed fund by State Street that tracks the performance of the S&P Biotechnology Select Industry Index. It was launched on Feb 6, 2006.
Performance
HRTX vs. XBI - Performance Comparison
Loading graphics...
HRTX vs. XBI - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
HRTX Heron Therapeutics, Inc. | -38.45% | -15.03% | -10.00% | -32.00% | -72.62% | -56.86% | -9.94% | -9.41% | 43.31% | 38.17% |
XBI SPDR S&P Biotech ETF | 4.76% | 35.89% | 1.01% | 7.60% | -25.87% | -20.45% | 48.33% | 32.56% | -15.28% | 43.77% |
Returns By Period
In the year-to-date period, HRTX achieves a -38.45% return, which is significantly lower than XBI's 4.76% return. Over the past 10 years, HRTX has underperformed XBI with an annualized return of -27.84%, while XBI has yielded a comparatively higher 9.32% annualized return.
HRTX
- 1D
- 7.27%
- 1M
- -32.76%
- YTD
- -38.45%
- 6M
- -36.50%
- 1Y
- -63.63%
- 3Y*
- -19.08%
- 5Y*
- -45.47%
- 10Y*
- -27.84%
XBI
- 1D
- 7.53%
- 1M
- 0.28%
- YTD
- 4.76%
- 6M
- 27.90%
- 1Y
- 58.08%
- 3Y*
- 19.00%
- 5Y*
- -1.29%
- 10Y*
- 9.32%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
HRTX vs. XBI — Risk / Return Rank
HRTX
XBI
HRTX vs. XBI - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Heron Therapeutics, Inc. (HRTX) and SPDR S&P Biotech ETF (XBI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| HRTX | XBI | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.98 | 2.02 | -3.00 |
Sortino ratioReturn per unit of downside risk | -1.58 | 2.70 | -4.28 |
Omega ratioGain probability vs. loss probability | 0.81 | 1.34 | -0.53 |
Calmar ratioReturn relative to maximum drawdown | -0.93 | 3.72 | -4.66 |
Martin ratioReturn relative to average drawdown | -1.56 | 13.98 | -15.54 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| HRTX | XBI | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -0.98 | 2.02 | -3.00 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.52 | -0.04 | -0.48 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | -0.37 | 0.29 | -0.67 |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.20 | 0.36 | -0.56 |
Correlation
The correlation between HRTX and XBI is 0.38, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Dividends
HRTX vs. XBI - Dividend Comparison
HRTX has not paid dividends to shareholders, while XBI's dividend yield for the trailing twelve months is around 0.34%.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
HRTX Heron Therapeutics, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
XBI SPDR S&P Biotech ETF | 0.34% | 0.37% | 0.15% | 0.02% | 0.00% | 0.04% | 0.20% | 0.00% | 0.28% | 0.24% | 0.26% | 0.61% |
Drawdowns
HRTX vs. XBI - Drawdown Comparison
The maximum HRTX drawdown since its inception was -99.96%, which is greater than XBI's maximum drawdown of -63.89%. Use the drawdown chart below to compare losses from any high point for HRTX and XBI.
Loading graphics...
Drawdown Indicators
| HRTX | XBI | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.96% | -63.89% | -36.07% |
Max Drawdown (1Y)Largest decline over 1 year | -69.18% | -13.39% | -55.79% |
Max Drawdown (5Y)Largest decline over 5 years | -97.08% | -55.04% | -42.04% |
Max Drawdown (10Y)Largest decline over 10 years | -98.71% | -63.89% | -34.82% |
Current DrawdownCurrent decline from peak | -99.94% | -26.17% | -73.77% |
Average DrawdownAverage peak-to-trough decline | -81.58% | -20.91% | -60.67% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 41.31% | 3.71% | +37.60% |
Volatility
HRTX vs. XBI - Volatility Comparison
Heron Therapeutics, Inc. (HRTX) has a higher volatility of 19.13% compared to SPDR S&P Biotech ETF (XBI) at 11.60%. This indicates that HRTX's price experiences larger fluctuations and is considered to be riskier than XBI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| HRTX | XBI | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 19.13% | 11.60% | +7.53% |
Volatility (6M)Calculated over the trailing 6-month period | 40.77% | 19.25% | +21.52% |
Volatility (1Y)Calculated over the trailing 1-year period | 65.09% | 29.24% | +35.85% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 87.85% | 32.23% | +55.62% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 74.47% | 32.15% | +42.32% |